Powered by the Evidence-based Practice Centers
SHARE:
FacebookTwitterFacebookPrintShare

Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment

Systematic Review ARCHIVED May 23, 2006

Documents

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Archived: Report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.

Excerpt

This review compares the efficacy and adverse effects of specific erythropoietic stimulants (i.e., epoetin [alfa or beta], darbepoetin alfa) when used to manage anemia in patients undergoing cancer therapy (i.e., chemotherapy and/or radiation). This review also addresses questions relevant to optimizing the use of erythropoietic stimulants as a general class: the outcomes of using alternative thresholds to initiate or discontinue treatment and whether there are early predictors of response to treatment.

Project Timeline

Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment

Jan 1, 2005
Topic Initiated
May 23, 2006
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/cancer-anemia/research

Select to copy citation